Avid Bioservices (CDMO) Tops Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- Wall St set to open lower as oil jump, high yields fuel inflation concerns
- Oil jumps as Middle East supply concerns persist amid shipping attacks
- Goldman Sachs sees 18% upside for Palantir on sovereign AI growth
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
- Citi names 5 top chip picks ahead of Q3 earnings
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- Sportradar to sell Synergy Sports coaching unit for $170M
- Rezolve AI (RZLV) Reiterated at Overweight by Cantor Fitzgerald on Positioning as Key Component in E-Commerce Stack
- Wall Street ends lower, off record highs, as Treasury yields climb
- Applied Digital (APLD) Tops Q1 EPS by 26c, Beats on Revenue
Avid Bioservices Reports Financial Results for First Quarter Fiscal 2019 and Recent Developments
September 10, 2018 4:05 PM EDT-- Fiscal 2019 Projected Revenue of $51 to $55 Million Reaffirmed --
-- Multiple Projects Advanced During the Quarter --
-- Initiated Operations of New Process Development Laboratories --
TUSTIN, Calif., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (NASDAQ: CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced financial results for the first quarter of... More



